Clinical trials: Head and Neck Tumours
Malignant Head and Neck Neoplasm, Mucositis
Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy
This randomized phase III trial studies how well gabapentin plus standard of care work compares to standard of care without Gabapentin in preventing inflammation of the mucous membranes (mucositis) in patients with stage III-IV…
- Conditions
- Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
- Trial name
- NCT02480114
- Testing
- Educational Intervention, Gabapentin, Pain Therapy
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Oral Cancer, Oropharyngeal Cancer
Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) in combination with chemotherapy and immunotherapy, prior to radical surgery, in enhancing the 2-year event-free…
- Trial name
- NCT07402538
- Testing
- Neoadjuvant treatment of SBRT plus chemoimmunotherapy followed by surgery and postoperative radiotherapy or chemoradiotherapy, Surgery and postoperative radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Sun Yat-sen University
Healthy Volunteer, Prostate Cancer
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes.
- Conditions
- Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer
- Trial name
- NCT04354064
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
HNSCC
Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)
A phase III, multicenter, randomized, open-label, french study comparing: Arm A : Radiotherapy alone (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction) (IMRT or protontherapy) Arm B: Radiotherapy (66 to 70 Gy; 5…
- Trial name
- SANTAL (NCT02998385)
- Testing
- Cisplatin, radiotherapy
- Where
- France
- Volunteers
- 342 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Esophageal Cancer
Photodynamic Therapy in Treating Patients With Early Esophageal Cancer
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective treatment for esophageal cancer.
- Trial name
- NCT00002935
- Testing
- porfimer sodium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Parathyroid Adenoma
Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism
The study aims are: 1. To compare the diagnostic performance of parathyroid four-dimensional CT (4D-CT), scintigraphy, and ultrasound in patients who underwent parathyroid surgery for primary hyperparathyroidism. 2.
- Trial name
- NCT02381925
- Sponsor
- Duke University
Advanced Cancer
Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
In this study, MGCD265, a new anticancer drug under investigation, is given daily to patients with advanced malignancies to study its safety profile.
- Trial name
- NCT00697632
- Testing
- MGCD265
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 180 people
- Sponsor
- Mirati Therapeutics Inc.
Adenocarcinoma - GEJ, Cancer of Esophagus
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer
An open label single arm phase II trial in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma which is MGMT deficient.
- Trial name
- ELEVATE (NCT04984733)
- Testing
- Temozolomide, Temozolomide 50mg/m2/day, Temozolomide 3 month
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- University of Southampton
Head and Neck Cancer, Lung Cancer
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021333
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Parotid Tumor
FArial NErf MRI in the Preoperative Assessment of PArotide Tumors
1. st visit: Inclusion, 3Tesla injected parotid MRI performed as part of routine care for characterization, to which two specific high resolution sequences will be added.
- Trial name
- NEFAPA (NCT04613349)
- Testing
- MRI
- Where
- France
- Volunteers
- 88 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Esophageal Cancer
Inter-observer Variation in Gross Tumor Delineation of Esophageal Cancer on MR, CT and PET CT
The aim of the study is to investigate inter-observer variation in gross tumor volume (GTV) delineation of oesophageal cancer on different imaging modalities - CT, PET CT and MR.Twenty-three consecutive patients with esophageal…
- Trial name
- NCT05611658
- Testing
- MR, PET CT
- Where
- Slovenia
- Volunteers
- 23 people
- Sponsor
- Institute of Oncology Ljubljana
Xerostomia, Head and Neck Cancers
Efficacy of Traditional Persian Medicine Preparation Versus Artificial Saliva for Radiation Induced Xerostomia
Head and neck cancers(HNC) is one of the most common cancers worldwide. Xerostomia is one of the most common side effect of radiation therapy among patients with HNC.
- Trial name
- NCT02854358
- Testing
- mixed powder of A. digitata and M. sylvestris, Hypozalix spray (artificial saliva)
- Volunteers
- 60 people
- Sponsor
- Shiraz University of Medical Sciences
Head & Neck Cancer
Radiotherapy In a Sitting Position for Enhanced Reproducibility
Qualitative, longitudinal and single-center study To explore the reproductibility and the acceptability of the sitting position for head and neck cancer patients through their experience of sitting and supine positions in the…
- Trial name
- RISE R (NCT07887048)
- Testing
- Simulation of radiotherapy session in sitting position
- Volunteers
- 16 people
- Sponsor
- Centre Leon Berard
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
Esophageal Cancer, Gastric Cancer
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and irinotecan in treating patients…
- Trial name
- NCT00004235
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Head and Neck (HNSCC)
HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC)
This is an international multi-centre, non-inferiority phase III randomized controlled trial comparing concurrent chemoradiation with high dose cisplatin (Arm A) vs.
- Trial name
- NCT07801235
- Testing
- 70 gy 35 fractions/7weeks+high dose of cisplatin, 81.6 Gy /68 fractions BID FOR 7 WEEKS
- Where
- Jordan
- Volunteers
- 604 people
- Sponsor
- King Hussein Cancer Center
Head and Neck Squamous Cell Carcinoma
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
- Trial name
- NCT06163534
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Tempus AI
Cancer of Head and Neck
Prognostic Value of 18FDG PET/CT Textural Indices in HNSCC
Head and neck (HN) cancer is the sixth most common malignancy worldwide, with around 800,000 new cases and 320,000 deaths in 2015.
- Trial name
- ImpactTextureO (NCT03378193)
- Where
- France
- Volunteers
- 284 people
- Sponsor
- University Hospital, Brest
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
This phase II trial is studying how well decitabine works in treating patients with metastatic papillary thyroid cancer or follicular thyroid cancer that has stopped responding to radioactive iodine.
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT00085293
- Testing
- Decitabine, Iodine I 131, Recombinant thyrotropin alfa
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.